Estimation of amyloid distribution by [¹⁸F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.

ABSTRACT: The deposition of the amyloid β-protein (Aβ) in senile plaques is one of the histopathological hallmarks of Alzheimer's disease (AD). Aβ-plaques arise first in neocortical areas and, then, expand into further brain regions in a process described by 5 phases. Since it is possible to identify amyloid pathology with radioactive-labeled tracers by positron emission tomography (PET) the question arises whether it is possible to distinguish the neuropathological Aβ-phases with amyloid PET imaging. To address this question we reassessed 97 cases of the end-of-life study cohort of the phase 3 [¹⁸F]flutemetamol trial (ClinicalTrials.gov identifiers NCT01165554, and NCT02090855) by combining the standardized uptake value ratios (SUVRs) with pons as reference region for cortical and caudat

SUBMITTER: Thal DR 

PROVIDER: S-EPMC6132944 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature